Avantogen Oncology, Inc., formerly known as Innovate Oncology, Inc., acquires, develops and seeks to commercialize compounds to treat various types of cancer. Prior to the May 26, 2006, Acquisition, the Company had been pursuing financing for a portfolio of products. The Company focused its resources on three particular product candidates: Chemo-resistance Inhibitor (RP101), Capridine beta and oral paclitaxel. In November 2006, after further evaluation of its existing pipeline, the Company decided to terminate its license agreement for oral paclitaxel. In connection with the May 26, 2006, Acquisition, the Company changed its name to Avantogen Oncology, Inc. from Innovate Oncology, Inc. (Innovate). In November 6, 2006, the Company, Gardant Pharnaceuticals, Inc. (Gardant) and Supratek Pharma, Inc. (SPI) entered into a termination of agreement and releases.